{"id":27064,"date":"2017-04-18T12:45:19","date_gmt":"2017-04-18T12:45:19","guid":{"rendered":"http:\/\/www.biphoo.com\/bipnews\/?p=27064"},"modified":"2017-04-18T12:45:19","modified_gmt":"2017-04-18T12:45:19","slug":"jj-revenue-misses-on-lower-than-expected-pharmaceutical-sales","status":"publish","type":"post","link":"https:\/\/www.biphoo.com\/bipnews\/business\/jj-revenue-misses-on-lower-than-expected-pharmaceutical-sales.html","title":{"rendered":"J&#038;J revenue misses on lower-than-expected pharmaceutical sales"},"content":{"rendered":"<h2 style=\"text-align: justify;\">\n\t<span style=\"font-size:22px;\"><span style=\"color: rgb(0, 0, 0);\"><span style=\"font-family: arial,helvetica,sans-serif;\"><strong>J&amp;J revenue misses on lower-than-expected pharmaceutical sales<\/strong><\/span><\/span><\/span><br \/>\n<\/h2>\n<p style=\"text-align: justify;\">\n\t<span style=\"color:#000000;\"><span style=\"font-size: 18px;\"><span style=\"font-family: arial,helvetica,sans-serif;\">Johnson &amp; Johnson, which is in the process of completing its $30 billion acquisition of Swiss biotech Actelion, reported on Tuesday<\/span><\/span><\/span>\n<\/p>\n<p style=\"text-align: justify;\">\n\t<span style=\"color:#000000;\"><span style=\"font-size: 18px;\"><span style=\"font-family: arial,helvetica,sans-serif;\">quarterly revenue that missed analysts&#39; estimates, hurt by lower demand for its pharmaceutical products.<\/span><\/span><\/span>\n<\/p>\n<p style=\"text-align: justify;\">\n\t<span style=\"color:#000000;\"><span style=\"font-size: 18px;\"><span style=\"font-family: arial,helvetica,sans-serif;\">The diversified healthcare company&#39;s sales rose to $17.77 billion in the first quarter from $17.48 billion a year earlier, but came in<\/span><\/span><\/span>\n<\/p>\n<p style=\"text-align: justify;\">\n\t<span style=\"color:#000000;\"><span style=\"font-size: 18px;\"><span style=\"font-family: arial,helvetica,sans-serif;\">below analysts&#39; average estimate of $18.04 billion, according to Thomson Reuters I\/B\/E\/S.<\/span><\/span><\/span>\n<\/p>\n<p style=\"text-align: justify;\">\n\t<span style=\"color:#000000;\"><span style=\"font-size: 18px;\"><span style=\"font-family: arial,helvetica,sans-serif;\">Pharmaceutical sales rose 0.8 percent to $8.25 billion, below Barclays estimate of $8.47 billion.<\/span><\/span><\/span>\n<\/p>\n<p style=\"text-align: justify;\">\n\t<span style=\"color:#000000;\"><span style=\"font-size: 18px;\"><span style=\"font-family: arial,helvetica,sans-serif;\">Net earnings in the quarter were $4.42 billion, or $1.61 per share, compared with $4.46 billion, or $1.59 per share, in the year-earlier<\/span><\/span><\/span>\n<\/p>\n<p style=\"text-align: justify;\">\n\t<span style=\"color:#000000;\"><span style=\"font-size: 18px;\"><span style=\"font-family: arial,helvetica,sans-serif;\">period.<\/span><\/span><\/span>\n<\/p>\n<p style=\"text-align: justify;\">\n\t<span style=\"color:#000000;\"><span style=\"font-size: 18px;\"><span style=\"font-family: arial,helvetica,sans-serif;\">Excluding items, the company earned $1.83 per share, beating Street expectations of $1.77 per share.<\/span><\/span><\/span>\n<\/p>\n<p style=\"text-align: justify;\">\n\t<span style=\"color:#000000;\"><span style=\"font-size: 18px;\"><span style=\"font-family: arial,helvetica,sans-serif;\">J&amp;J is the first among major pharmaceutical companies to report quarterly results, a month after the Republican attempt to overhaul<\/span><\/span><\/span>\n<\/p>\n<p style=\"text-align: justify;\">\n\t<span style=\"color:#000000;\"><span style=\"font-size: 18px;\"><span style=\"font-family: arial,helvetica,sans-serif;\">the U.S. healthcare system spectacularly failed, although a renewed effort is said to be in the works.<\/span><\/span><\/span>\n<\/p>\n<p style=\"text-align: justify;\">\n\t<span style=\"color:#000000;\"><span style=\"font-size: 18px;\"><span style=\"font-family: arial,helvetica,sans-serif;\">The company&#39;s shares slipped nearly 1 percent to $124.60 in premarket trading.<\/span><\/span><\/span>\n<\/p>\n<p style=\"text-align: justify;\">\n\t<span style=\"font-size:8px;\"><span style=\"color: rgb(0, 0, 0);\"><span style=\"font-family: arial,helvetica,sans-serif;\">Source:-<\/span><\/span>http:\/\/www.reuters.com\/article\/us-johnson-johnson-results-idUSKBN17K15T<\/span><\/p>\n<div class=\"fb-background-color\">\n\t\t\t  <div \n\t\t\t  \tclass = \"fb-comments\" \n\t\t\t  \tdata-href = \"https:\/\/www.biphoo.com\/bipnews\/business\/jj-revenue-misses-on-lower-than-expected-pharmaceutical-sales.html\"\n\t\t\t  \tdata-numposts = \"10\"\n\t\t\t  \tdata-lazy = \"true\"\n\t\t\t\tdata-colorscheme = \"light\"\n\t\t\t\tdata-order-by = \"social\"\n\t\t\t\tdata-mobile=true>\n\t\t\t  <\/div><\/div>\n\t\t  <style>\n\t\t    .fb-background-color {\n\t\t\t\tbackground: #ffffff !important;\n\t\t\t}\n\t\t\t.fb_iframe_widget_fluid_desktop iframe {\n\t\t\t    width: 630px !important;\n\t\t\t}\n\t\t  <\/style>\n\t\t  ","protected":false},"excerpt":{"rendered":"<p>J&amp;J revenue misses on lower-than-expected pharmaceutical sales Johnson &amp; Johnson, which is in the process of completing its $30 billion acquisition of Swiss biotech Actelion, reported on Tuesday quarterly revenue that missed analysts&#39; estimates, hurt by lower demand for its pharmaceutical products. The diversified healthcare company&#39;s sales rose to $17.77 [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":27066,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[9],"tags":[17051,699,146,17053,3242,17052,7963],"class_list":["post-27064","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-business","tag-best-news","tag-breaking-news","tag-business-news","tag-jj-revenue-misses-on-lower-than-expected-pharmaceutical-sales","tag-latest-news","tag-live-news-online","tag-top-news"],"_links":{"self":[{"href":"https:\/\/www.biphoo.com\/bipnews\/wp-json\/wp\/v2\/posts\/27064","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.biphoo.com\/bipnews\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.biphoo.com\/bipnews\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.biphoo.com\/bipnews\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.biphoo.com\/bipnews\/wp-json\/wp\/v2\/comments?post=27064"}],"version-history":[{"count":0,"href":"https:\/\/www.biphoo.com\/bipnews\/wp-json\/wp\/v2\/posts\/27064\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.biphoo.com\/bipnews\/wp-json\/wp\/v2\/media\/27066"}],"wp:attachment":[{"href":"https:\/\/www.biphoo.com\/bipnews\/wp-json\/wp\/v2\/media?parent=27064"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.biphoo.com\/bipnews\/wp-json\/wp\/v2\/categories?post=27064"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.biphoo.com\/bipnews\/wp-json\/wp\/v2\/tags?post=27064"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}